Neurosense Therapeutics Ltd
Save
31.45M
Market cap
Current P/E
Forward P/E

About

Health care
Sector
Biotechnology
Industry

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of treatment for patients suffering from debilitating neurodegenerative diseases. Its lead product, PrimeC, is a novel oral formulation that has completed Phase IIa clinical trials for the treatment of amyotrophic lateral sclerosis. The company's preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease.

Similar securities

Based on sector and market capitalization

Report issue